Skip to main content
  • English
  • Español
Oryzon
  • Company
    • Overview
    • Strategy
    • Team
  • Epigenetics
    • Epigenetics
    • LSD1
  • Programs
    • Pipeline
    • Iadademstat
    • Vafidemstat
    • Collaborations
    • Publications
  • Patients
    • Clinical Trials
  • Investors
    • Share Information
      • Share Performance
      • Shares and Capital Structure
      • Dividends
      • Share Issues
      • Takeover Bids
      • Shareholdings
    • Financial Information
      • Financial Results and Accounts
      • Public Periodic Information
      • Average supplier payment period
    • CNMV Filings
    • Analyst Coverage
    • Corporate Governance
      • General Shareholders Meeting
      • Board of Directors
      • Board Committees
      • Shareholder Agreements
      • Annual Corporate Governance Reports
      • Annual Director Remuneration Reports
    • Corporate Social Responsibility
  • News & Events
    • Press releases
    • Events
  • Contact
    • Contact
    • Email Alerts
    • Join us

Breadcrumb

  1. Home
19 January 2024

ORYZON to Host KOL Event on Phase IIb PORTICO Topline Study Results of Vafidemstat in Borderline Personality Disorder on January 25, 2024

7 January 2024

Webcast/Conference call hold by Oryzon to Discuss Topline Results from Phase IIb PORTICO Study of vafidemstat in Borderline Personality Disorder

5 January 2024

ORYZON Announces Topline Results from Phase IIb PORTICO study of vafidemstat in Borderline Personality Disorder (BPD)

30 January 2024

Invest Securities Biomed Forum 2024

Paris

France

8-11 January 2024

42nd Annual J.P. Morgan Healthcare Conference

Westin St. Francis Hotel, San Francisco

CA

United States

8-10 January 2024

Biotech Showcase-2024

Hilton Union Square hotel, San Francisco

CA

United States

8-10 January 2024

13rd Annual LifeSci Advisors Corporate Access Event

Beacon Grand Hotel, San Francisco

CA

United States

7 January 2024

7th Sachs Annual Neuroscience Innovation Forum

Marine’s Memorial Club, San Francisco

CA

United States

3 January 2024

ORYZON to provide corporate progress updates at several events in January

4 December 2023

ORYZON awarded with a grant for ORY-4001 from the ALS Association in the U.S.

Pagination

  • First page « First
  • Previous page ‹ Previous
  • Page 11
  • Page 12
  • Page 13
  • Page 14
  • Current page 15
  • Page 16
  • Page 17
  • Page 18
  • Page 19
  • Next page Next ›
  • Last page Last »
Subscribe to
Logo Oryzon
  • Company
    • Overview
    • Strategy
    • Team
  • Epigenetics
    • Epigenetics
    • LSD1
  • Programs
    • Pipeline
    • Iadademstat
    • Vafidemstat
    • Collaborations
    • Publications
  • Patients
    • Clinical Trials
  • Investors
    • Share Information
    • Financial Information
    • CNMV Filings
    • Analyst Coverage
    • Corporate Governance
    • Corporate Social Responsibility
  • News & Events
    • Press releases
    • Events
  • Contact
    • Contact
    • Email Alerts
    • Join us
  • © Oryzon Genomics, S.A. - All Rights Reserved

    • Legal
    • Privacy Policy
    • Cookie Policy
    • Ethics Channel